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Type II diabetes (T2D) and major depressive disorder (MDD)
are often co-morbid. The reasons for this co-morbidity are
unclear. Some studies have highlighted the importance of envi-
ronmental factors and a causal relationship between T2D and
MDDhas also been postulated. In the present study we set out to
investigate the shared aetiology between T2D and MDD using
Mendelian randomization in a population based sample, Gen-
eration Scotland: the Scottish FamilyHealth Study (N¼ 21,516).
Eleven SNPs found to be associated with T2D were tested for
association with MDD and psychological distress (General
Health Questionnaire scores). We also assessed causality and
genetic overlap between T2D and MDD using polygenic risk
scores (PRS) assembled from the largest available GWAS sum-
mary statistics to date. No single T2D risk SNP was associated
with MDD in the MR analyses and we did not find consistent
evidence of genetic overlap between MDD and T2D in the PRS
analyses. Linkage disequilibrium score regression analyses sup-
ported these findings as no genetic correlation was observed
betweenT2DandMDD(rG¼ 0.0278 (S.E. 0.11),P-value¼ 0.79).
As suggested by previous studies, T2D andMDDcovariancemay
be better explained by environmental factors. Future studies
would benefit from analyses in larger cohorts where stratifying
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by sex and looking more closely at MDD cases demonstrating
metabolic dysregulation is possible.
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INTRODUCTION
Major Depressive Disorder (MDD) is a complex psychiatric dis-
order characterized by persistent low mood, and is the second
leading cause of disability worldwide [Ferrari et al., 2013]. The
precise biological cause ofMDD is unknownbut significant overlap
between MDD and somatic diseases has been noted [Goodwin,
2006]. Type II diabetes (T2D) has significant co-morbidity with
MDD and the odds of developing depression in T2D individuals
are twice that of non-type II diabetics [Anderson et al., 2001].
Bidirectional studies have found that the relative hazard for
developing diabetes is 1.10 for each 5 unit increase in CES-D
scores (self-reported depressive symptoms) and the relative hazard
for MDD was 1.54 for untreated T2D [Golden et al., 2008]. The
cause of this co-morbidity is not fully understood. Shared envi-
ronmental and genetic risk factors have been hypothesized to
underlie MDD and T2D. Furthermore, a causal relationship
may exist whereby the symptoms of diabetes cause depression
in some individuals, and vice-versa. By determining the underlying
factors that promote the co-occurrence of T2D and MDD we may
be able to understandmore about the biological basis of these traits.
Twin studies have traditionally been used to estimate the genetic
contribution to the association betweenMDD and T2D. A study of
male twins found no influence of genetic factors on the co-
expression of T2D and MDD [Scherrer et al., 2011]. Similarly, a
study of Swedish twins found no effect of genetic factors, but that
unique environmental factors significantly contribute toMDD and
T2D [Mezuk et al., 2015]. A recent large study of Swedish and
Danish Twin population registries found evidence of individual-
specific environmental factors in males whereas the correlations in
females were due to genetic factors [Kan et al., 2016].
Large genome-wide association studies (GWAS) of T2D and
MDD have found that a substantial portion of genetic suscepti-
bility is attributable to common genetic variants. A GWAS of
T2D involving 38,840 cases and 114,981 controls found the
proportion of genetic variance attributable to common genetic
variants to be 49% on the liability scale [Morris et al., 2012].
Unlike MDD GWAS, which have only identified two genome-
wide significant loci to be associated with MDD in Chinese
women [CONVERGE, 2015], GWAS of T2D have found 70
loci to be significantly associated with increased risk for T2D.
These 70 loci account for 10.9% of the disease variance of T2D, a
substantial portion of the 49% of variance explained by all
common SNPs [Morris et al., 2012]. GWAS summary data
can be used to test for genetic overlap between traits by creating
polygenic risk scores (PRS). One study used 20 SNPs robustly
associated with T2D and created an unweighted PRS however
this was not significantly associated with depression in a large
sample of 17,000 individuals [Samaan et al., 2015].
There may be a causal relationship between T2D and MDD.
Individuals with depression may be more likely to have a poor diet
[Sharma and Fulton, 2013], may exercise less or smoke; all of which
increase risk for T2D. Conversely,MDDmay arise from the distress
caused by managing the symptoms of T2D. It is difficult to infer
causality from observations alone as confounding factors such as
socio-demographics or education [Kessler and Bromet, 2013] may
influence correlations.
Mendelian randomization (MR) is a technique that uses genetic
factors as proxies for an environmental exposure of interest. MR
assumes no pleiotropy; genetic factors should only be associated
with the phenotype of interest via the environmental exposure.
According to the laws of Mendelian inheritance regarding segre-
gation and independent assortment, genetic variants will not be
associatedwith confounding factors and therefore can help provide
evidence of causal relationships [Smith and Ebrahim, 2003].
Individual SNPs can be weak instruments to investigate causality
as they typically have small effects on phenotype expression and
require large sample sizes to robustly detect associations. Polygenic
risk scores (PRS), which aggregate the effect of thousands of SNPs
into a score representing the overall burden of risk alleles an
individual carries, have greater power to detect association between
traits of interest. One limitation of using PRS to explore causal
relationships is the risk of pleiotropy: associations may arise from
causality or pleiotropy, particularly when thousands of SNPs
comprise the PRS. Another technique, linkage disequilibrium
(LD) score regression uses the LD information from SNPs to
compute genetic correlations between traits of interest from
GWAS summary statistics [Bulik-Sullivan et al., 2015]. This
method is typically better powered to detect genetic correlations
compared to PRS and provides more reliable estimates of the
magnitude of genetic overlap between traits.
The aim of this study was to investigate causal relationships and
genetic overlap between T2D and MDD in the population based
cohort, Generation Scotland: the Scottish Family Health Study
(GS:SFHS) (N¼ 21,516) [Smith et al., 2006; Lee et al., 2013]. Using
three techniques; MR, PRS, and LD score regression we aim to
build evidence to explore the relationship between T2D and MDD
with the hope of understanding more about the biological basis of
these traits which will inform treatment of co-morbid cases of T2D
and MDD.
MATERIALS AND METHODS
Sample Description
Generation Scotland. The Scottish Family Health Study (GS:
SFHS) is a family and population-based study that recruited from
the lists of General Practitioners throughout Scotland; the protocol
for recruitment is described in detail elsewhere [Smith et al., 2006;
Lee et al., 2013]. All components of GS:SFHS have received ethical
approval from the NHS Tayside Committee on Medical Research
Ethics (RECReferenceNumber: 05/S1401/89).Written consent for
the use of data was obtained from all participants. GS:SFHS
consists of 23,690 individuals over the age of 18 of whom
21,516 attended the research clinic. Genome-wide genotype data
were available for 19,858 individuals.
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Phenotype Definition
Depression and psychological distress phenotypes. The pres-
ence or absence of MDD was determined using the structured
clinical interview for the Diagnostic and Statistical Manual of
Mental Disorders (SCID) [First et al., 1997]. A brief screening
questionnaire initially asked participants, “Have you ever seen
anybody for emotional or psychiatric problems?” and “Was there
ever a time when you, or someone else, thought you should see
someone because of the way you were feeling or acting?” 21.7% of
participants who answered yes to either of these questions went on
to complete the SCID [First et al., 1997]. If they answered no to
both of these questions, they were assigned control status. Individ-
uals with a diagnosis of bipolar disorder were removed from this
study. The General Health Questionnaire (GHQ-28) was com-
pleted by 21,201 of participants providing a measure of current
psychological distress [Goldberg and Hillier, 1979]. The GHQ-28
consists of four subscales designed to assess: (A) somatic symp-
toms, (B) anxiety and insomnia, (C) social dysfunction and (D)
“severe depression.” Total scores across subscales were used to
provide a measure of current psychological distress using the GHQ
scoring method. Scores were transformed towards normality using
the BoxCox transformation procedure implemented in the MASS
package in R. Continuous variables were scaled to have a mean of
0 and a standard deviation of one such that the reported beta-
coefficients are standardized.
Diabetes phenotype. Diabetes andmedication use in GS:SFHS
were self-reported. The Scottish Diabetes Research Network
(SDRN) provided information about T2D diagnoses which was
linked to the Generation Scotland database [Anwar et al., 2011].
915 individuals in GS:SFHS were assigned T2D status using self-
report data, SRDN diagnosis and sufficient medication informa-
tion to distinguish between T1D and T2D (individuals using
insulin were likely to be T1D). Individuals whose diabetes status
(T1D vs T2D) was unclear or were confirmed as T1D using SDRN
data were excluded from the analysis. Control individuals were
those with no self-reported diabetes, no evidence of diabetic
medication use and no diagnosis from SDRN.
Genotype Acquisition
Blood samples were obtained using standard operating procedures
and were stored at the Wellcome Trust Clinical Research Facility
Genetics Core (www.wtcrf.ed.ac.uk). Genotyping was carried out
using the Illumina HumanOmniExpressExome-8v1.0 BeadChip
and Infinum chemistry24 and processed using the IlluminaGeno-
meStudio Analysis software v2011.1 (Illumina, San Diego, CA).
Quality control removed SNPs with <98% call rate, SNPs with a
Hardy–Weinberg P-value 1 106 and a minor allele frequency
greater than 1%. After quality control, 561,125 SNPs were available
for analyses. The details of blood collection andDNA extraction are
provided elsewhere [Smith et al., 2006].
Mendelian Randomisation
The list of T2D risk SNPs selected for MR was made based on
evidence for prior association with T2D. Single nucleotide poly-
morphisms (SNPs) found to be associated (P 5 108) with
T2D in two GWAS (comprising 38,840 cases and 114,981 controls
[Morris et al., 2012] and 47,979 cases and 139,611 controls
comprising a trans-ancestry GWAS [Mahajan et al., 2014]) were
used to performMR by testing for their association withMDD and
current psychological distress. The list consisted of 10 indepen-
dently associated SNPs from DIAGRAM GWAS that were signifi-
cant at a genome-wide level [Morris et al., 2012], and seven further
independent loci identified in the DIAGRAM trans-ancestry T2D
GWAS [Mahajan et al., 2014]. 11/17 SNPs were directly genotyped
in GS:SFHS and these were the SNPs used in this study (Table II).
These SNPs have been validated for their association with T2D
using a two-stage meta-analyses replication within the original
GWAS studies. All SNPs have been found to be associated in
European populations and are therefore suitable proxies for
T2D in the present study. Using a Bonferroni correction for
multiple testing we calculated the threshold for statistical signifi-
cance for theMR analyses to be (P< 0.0045 [0.05/11]). PLINKwas
used to calculate the number ofminor alleles to create a variable for
association testing [Purcell et al., 2007]. Depression-associated
SNPs were not tested for association with T2D as the only two
robustly associated MDD SNPs were identified in a sample of
Chinese women, and do not replicate in the largestMDDGWAS of
European descent [CONVERGE, 2015].
SNPs were tested for their association with MDD and GHQ-28
scores in GS:SFHS using mixed linear models implemented in AS-
Reml-R (www.vsni.co.uk/software/asreml) software package. Age,
sex and SNP allele count were fixed effects. To control for related-
ness between individuals family structure was fitted as a random
effect by creating an inverse relationship matrix using pedigree
kinship information. Wald’s conditional F-test was used to calcu-
late the significance of fixed effects. If T2D SNPs are associatedwith
MDD via a causal pathway involving diabetes then the association
should only be present in diabetic individuals. A sensitivity analysis
was carried out to determine these effects by testing for SNP
association in diabetic and control individuals separately. As there
were only 130 individuals in GS:SFHS with both diabetes and
depression the sensitivity analysis was only performed for GHQ
scores. If an association is observed in non-diabetics then the SNPs
may affect diabetes and depression independently (pleiotropy) and
the assumptions of MR are violated.
PRS Analysis
T2D and MDD PRS were computed for 19,858 genotyped indi-
viduals in GS:SFHS. T2D scores were created based on the DIA-
GRAM T2D GWAS summary data comprising 12,171 cases and
56,862 controls individuals [Morris et al., 2012] and MDD scores
were computed based on the largest most recent MDD GWAS
(N¼ 18,759) [Ripke et al., 2012]. Briefly, PRS were created in
PLINK according to previously described protocols [Purcell et al.,
2009]. Prior to creating scores, all strand-ambiguous SNPs were
removed from the GS:SFHS genotypes and SNPs were linkage
disequilibrium pruned using clump-based pruning (r2¼ 0.25,
300 kb window). Five PRS were created for each trait using P-value
cut-off thresholds of P 0.01, 0.05, 0.1, 0.5 and 1 for association in
the original T2D andMDDGWAS. The association analyses of PRS
with T2D/MDD were performed in AS-REML-R fitting family as a
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random effect as previously described. When T2D PRS was tested
for association with GHQ or depression status, diabetes status was
fit as a fixed effect covariate. Similarly, when MDD PRS was tested
for association with diabetes status, depression status was fit as a
fixed effect covariate. All models were controlled for age, sex,
and four multidimensional scaling components to control for
population stratification. The proportion of phenotypic variance
explained by polygenic risk score was calculated bymultiplying the
profile score by its corresponding regression coefficient and esti-
mating its variance. This value was then divided by the variance of
the observed phenotype to yield a coefficient of determination
between 0 and 1 [Nakawaga and Schielzeth, 2013]. Using a
Bonferroni correction formultiple testingwe calculated the thresh-
old for statistical significance for the PRS analyses to be (P< 0.0017
[0.05/30]).
LD Score Regression
GWAS summary statistics for the DIAGRAM T2D GWAS and the
PGCMDDGWAS were used to perform LD score regression. This
method uses the correlational nature of SNPs such that SNPs with
high LD will have higher average x2 statistics than those with low
LD. To estimate genetic correlations the product of two z-scores
from GWAS of two traits can be regressed onto the LD score and
the slope of the regression used to estimate genetic covariance
[Bulik-Sullivan et al., 2015]. The interceptwas left unconstrained as
the degree of sample overlap between DIAGRAM T2D and PGC
MDD cohorts was unknown.
RESULTS
Nine hundred and fifteen individuals in Generation Scotland were
classed as Type II diabetics and 2,714 individuals met the criteria
for a lifetime diagnosis of MDD. There was a significantly greater
prevalence of MDD amongst T2D individuals in GS:SFHS (14.2%
in T2D cases vs. 11.4% in T2D controls) and those with T2D had
significantly higher GHQ scores (2.93 vs. 2.30) (Table I).
Of the 11 SNPs previously identified as demonstrating associa-
tion with T2D, only one was nominally associated with MDD in
GS:SFHS. The A allele of rs6808574 was found to be negatively
associated with MDD in GS:SFHS (beta¼0.008, P¼ 0.02)
(Table II). This is the same allele found to be associated with
decreased risk for T2D in the trans-ancestry GWAS of T2D. No
other SNPs were found to be associated with MDD in the MR
analysis. Only one SNPwas nominally associatedwith GHQ scores,
rs3130501. The A allele of this SNP was associated with lower GHQ
scores (beta¼0.025, P-value¼ 0.03) (Table III) in GS:SFHS and
with decreased risk for T2D in the trans-ancestry GWAS of T2D.
Further analyses of rs3130501 and GHQ scores show it was
associatedwithGHQ score in non-diabetic controls (beta¼0.03,
P-value¼ 0.01). However, although diabetic cases showed a stron-
ger correlationwithGHQ score (beta¼0.04) this associationwas
not significant (P¼ 0.56) as only 915 diabetic cases were available
for analysis in GS:SFHS (Table III). This sensitivity analysis sug-
gests that any relationship between this SNP and GHQ arises
via pleiotropic effects rather than a causal relationship between
diabetes and psychological distress. None of the associations
between T2D SNPs and MDD or GHQ remained significant after
correction for multiple testing. Thus, MR analysis provided no
evidence for a causal relationship between T2D and MDD.
PRS analyses found the T2D PRS to be associated with T2D in
GS:SFHS at 5 out of 5 P-value thresholds with the P 0.05
threshold explaining most of the variance in T2D status (beta¼
0.013, r2¼ 0.004, P-value¼ 1 1018), indicating that the T2D
PRS is a valid instrument for use in GS:SFHS. MDD PRS was
associated with MDD at 4 out of 5 P-value thresholds in GS:SFHS
with the P-value threshold explaining most of the variance being
TABLE I. Comparison of Diabetic Individuals and Control Individuals for Measures of Depression and Psychological Distress in
Generation Scotland
Diabetic cases (N¼ 915) Controls (N¼ 22,582) P-value
Age (S.E.) 59.4 (0.41) 47.3 (0.102) 6.05 10125
Female 468 (51.2%) 13,412 (59.3%) 2.2 1010
MDD 130 (14.2%) 2567 (11.4%) 2.6 106
MDD episode count 12.2 (1.49) 7.7 (0.27) 0.00012
GHQ total (S.E.) 2.93 (0.175) 2.3 (0.028) 7.9 108
MDD age of onset (S.E.) 36.6 (1.13) 31.2 (0.26) 0.74
TABLE II. Mendelian Randomisation Analyses of T2D associated
SNPs With MDD Status in GS Controlling for Age and Sex
SNP Beta (S.E.) Z-ratio P-value
rs10401969 0.007 (0.007) 0.97 0.33
rs10842994 0.003 (0.005) 0.57 0.57
rs12970134 0.003 (0.004) 0.79 0.43
rs2796441 0.0009 (0.004) 0.25 0.80
rs3130501 0.007 (0.004) 1.68 0.09
rs4275659 0.001 (0.004) 0.26 0.79
rs516946 0.003 (0.004) 0.50 0.56
rs6808574 0.008 (0.003) 2.29 0.02
rs702634 0.001 (0.004) 0.33 0.74
rs7177055 0.003 (0.004) 0.66 0.51
rs7202877 0.0009 (0.006) 0.15 0.88
Nominally significant SNPs are highlighted in bold.
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P 1 (beta¼ 0.011, r2¼ 0.003, P-value¼ 3 105). Similarly, this
MDD PRS explained most of the variance in GHQ scores in GS:
SFHS (beta¼ 0.046, r2¼ 0.053, P-value¼ 6 1010) (Table IV).
Cross association analyses found the T2D PRS to be nominally
associated with MDD status at 3 out of 5 p-value thresholds,
the most strongly associated at P 1 (beta¼ 0.007, r2¼ 0.001,
P-value¼ 0.015), after controlling for diabetes status, however
this was not significant after correction for multiple testing.
No association between T2D PRS and GHQ scores were found.
MDD PRS were not significantly associated with T2D status in
GS:SFHS (Table V).
LD score regression using DIAGRAM T2D and PGC-MDD
GWAS summary statistics found no evidence to suggest shared
genetic effects between T2D and MDD (Genetic Correlation
(rG)¼ 0.0278 (S.E. 0.11), P-value¼ 0.79).
DISCUSSION
Using genetic factors to analyse the relationship between T2D and
MDD we find little evidence that T2D is causally related to
depression or psychological distress among GS:SFHS individuals.
One SNP, rs6808574, was nominally associated with MDD and
another, rs3130501, with GHQ. However, the association between
rs3130501 and GHQ scores was found in non-diabetic individuals
indicating that the association arises from genetic pleiotropy rather
than a causal relationship between T2D and psychological distress
as these individuals are not self-reporting T2D or registered in the
SDRNas being diabetic. As nine out of elevenT2D-associated SNPs
failed to show any association with MDD or GHQ scores it would
suggest that T2D is not causally related to depression or psycho-
logical distress. There was little evidence of genetic association
between MDD and T2D when we applied a PRS analysis. T2D PRS
showed some nominal association with MDD status at the less
stringent inclusion thresholds of P 0.1. The MDD PRS was not
associated with T2D status in GS:SFHS at any of the five p-value
thresholds. LD score regression found no evidence of genetic
overlap between T2D and MDD using DIAGRAM and PGC
summary statistics. These findings suggest there is little genetic
overlap between T2D and MDD.
Our results are partially supported by other studies utilizing twin
registries to examine the genetic contribution to MDD and T2D
covariance. A study of Swedish twins found that non-shared
environmental factors are responsible for the majority of the
association between T2D and MDD [Mezuk et al., 2015]. Another
study of Swedish and Danish twins found a genetic contribution to
the covariance in T2D and MDD amongst females in the Swedish
sample whereas unique environmental effects were more influen-
tial in male twins. Genetic effects were contributing to T2D and
MDD in males and females separately in the Danish sample,
however, they found differences in the genetic effects between
males and females in both samples, suggesting that future studies
may benefit from stratifying by sex [Kan et al., 2016]. Similar to our
study, a PRS analysis in a large sample including>3000MDD cases
found no association between a T2D PRS comprising 20 SNPs and
MDD [Samaan et al., 2015].
We were not able to find consistent evidence for genetic overlap
between T2D andMDDor evidence of a causal relationship leading
from T2D toMDD. There are a number of limitations to our study
which may have reduced our ability to detect an association
between T2D and MDD. We were constrained by the number
of diabetic individuals in GS:SFHS, only 915. Furthermore, we had
to distinguish between T1D andT2Dbased onmedication data and
links to the SRDN database. Individuals with an ambiguous T1D/
T2D status were removed but it is remains a possibility that there is
some clinical heterogeneity unaccounted for in our sample. The
SNPs used in the MR analyses had, individually, a small effect on
risk for T2D in the original GWAS (OR¼ 1.06–1.13). Such small
effects require large sample sizes to detect association and therefore
a sample with more MDD cases should be used to test for a causal
relationship between T2D and MDD in future studies.
Another limitation was the sensitivity of the MDD PRS com-
pared to the T2D PRS due to the number of individuals in the
original GWAS (MDD N¼ 18,759 vs. T2D N¼ 149,821). With a
larger MDDGWAS and more T2D cases we may have uncovered a
TABLE III. Association of T2D Associated SNPs With GHQ Total Scores in GS Full Cohort, Diabetics Only and Controls Only
Full Sample Diabetics only Controls only
SNP Beta (S.E.) Z-ratio P-value Beta (S.E.) Z-ratio P-value Beta (S.E.) Z-ratio P-value
rs10401969 0.014 (0.02) 0.66 0.51 0.10 (0.1) 1.03 0.30 0.009 (0.02) 0.44 0.66
rs10842994 0.0019 (0.01) 0.15 0.88 0.002 (0.07) 0.03 0.98 0.004 (0.01) 0.31 0.75
rs12970134 0.013 (0.01) 1.12 0.26 0.07 (0.06) 1.19 0.24 0.013 (0.01) 1.08 0.27
rs2796441 0.016 (0.01) 1.55 0.12 0.07 (0.05) 1.30 0.20 0.013 (0.01) 1.29 0.20
rs3130501 0.025 (0.01) 2.17 0.03 0.04(0.07) 0.59 0.56 0.03 (0.01) 2.56 0.01
rs4275659 0.018 (0.01) 1.62 0.11 0.053 (0.06) 0.84 0.40 0.02 (0.01) 1.65 0.10
rs516946 0.017 (0.01) 1.37 0.17 0.054 (0.07) 0.81 0.42 0.02 (0.01) 1.85 0.06
rs6808574 0.014 (0.01) 1.31 0.19 0.014 (0.06) 0.24 0.81 0.02 (0.01) 1.39 0.16
rs702634 0.009 (0.01) 0.78 0.43 0.001 (0.06) 0.02 0.98 0.006 (0.01) 0.56 0.57
rs7177055 0.009 (0.01) 0.79 0.43 0.12 (0.06) 2.09 0.04 0.005 (0.01) 0.43 0.66
rs7202877 0.014 (0.02) 0.82 0.41 0.03 (0.10) 0.29 0.77 0.01 (0.02) 0.60 0.55
Controlled for age and sex. Nominally significant SNPs highlighted in bold.
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genetic overlap using PRS. We did find a nominal association
between T2D PRS and MDD at higher p-value thresholds and
therefore this should be investigated further using a larger sample.
However, LD score regression using the same GWAS summary
statistics use to create PRS in this study found no genetic overlap
between T2D and MDD. Another limitation is that although we
used medication data and linkage to the SDRN to assign T2D case
status, for some individuals self-report was the only measure
available and this may have led to some individuals being
misclassified.
A recent study of depressive symptoms and T2D risk in 2525
Canadian individuals found that the risk for T2D was only in-
creased in those reporting depressive symptoms and presenting
with metabolic dysregulation, characterized by obesity, high blood
pressure, elevated blood sugar andhigh triglycerides [Schmitz et al.,
2016]. It may be that there is a sub-type of MDD characterized by
metabolic dysregulation which has genetic overlap with T2D.
Future studies of larger cohorts may benefit from stratifying
depression according to metabolic profile and looking at the
sources of covariance with T2D. Future MR studies would also
benefit from investigating the association betweenMDDassociated
SNPs and T2D. We were unable to study this, as no robustly
associated genome-wide significant SNPs are associatedwithMDD
in individuals of European ancestry. As sample sizes for MDD
GWAS become larger and more loci are identified these analyses
can be carried out to determine whether a causal relationship
leading from MDD to T2D exists. Future studies of larger cohorts
would benefit from stratifying by sex and byMDD subtypes such as
metabolic dysregulation to understand the co-morbidity between
T2D and MDD.
We conclude that there is little evidence for genetic overlap
between T2D and MDD or a causal relationship leading from
T2D to MDD. As suggested by other studies, the co-expression of
T2D and MDD is likely to be influenced by unique environmental
factors.
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